Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (190 kB)
Prospectus (1181 kB)
Periodic reports
Sustainability SFDR (875 kB)
Annual review (PF) (2827 kB)
Semi-annual report (PF) (200 kB)
Marketing material
Sustainability profile
Brief fund information
Summary SFDR (171 kB)
Handelsbanken Hälsovård Tema (A10 EUR)
Legal name: Handelsbanken Hälsovård Tema (A10 EUR)
Equity Fund Registered in Sweden (UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed and invests globally in equities issued by companies within the healthcare sector. As a result, the fund has a currency exposure to these markets. The healthcare sector refers to the pharmaceutical, medical technology, biotech, service and other healthcare-related branches.
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund manager
Christopher Sundman Experience in the fund industry 1987. Portfolio Manager since 1 August 2022.
Fund manager
Caroline Banér Experience in the fund industry 2009. Portfolio Manager since 1 October 2024.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
31.10.2024
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
The fund has sustainable investments as its objective. Accordingly, the fund invests in companies with products and services that are considered as contributing positively to the direct fulfillment of one or several of the targets in Agenda 2030. Refer to the fund's prospectus for additional information. The fund is reported as an Article 9 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). Read more |
|
30.09.2024
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 27.11.2024 | 1 week | 1 month | 3 months | 2024 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 43.14 EUR | 3.03% | -0.80% | -4.35% | 15.59% | 18.84% | - | - |
Portfolio 16.10.2024
Portfolio manager comments — Q3 2024P
Fund performance was marginally negative during the quarter. Among the positive contributors were UnitedHealth Group and HCA Healthcare, which both posted strong performance after presenting stronger than expected reports. HCA also raised its full-year outlook. Sanofi also contributed positively, partly through a strong report, as well as with promising study results for the drug candidate Tolebrutinib for the treatment of a specific type of multiple sclerosis (MS).
On the negative side were holdings in Edwards Lifesciences and Dexcom, which were both hit hard after reporting weaker than expected results and lowered their forecasts. Novo Nordisk and Eli Lilly, active within obesity/diabetes also lagged, as did AstraZeneca and Daiichi Sankyo, which declined after one of the studies for Dato-Dxd did not meet the market’s expectations. However, it is worth noting that these companies have had positive momentum thus far this year and are among the fund’s strongest contributors to date in 2024. During the month we sold the holding in Dexcom and switched the position in Zimmer Biomet to Stryker.
In the middle of August, CMS published the negotiated prices for the ten drugs included in the list for the Inflation Reduction Act (IRA) in the US. In general, the discounts were in line with market expectations and we know that several of the drugs on the list have patents that will expire in the near term.
Portfolio distribution 31.10.2024
Geographic breakdown 31.10.2024
